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Abstract
Background: Lipocalin 2 (Lcn2) is a bacteriostatic factor that may also modulate cellular function, however, little is
known concerning the expression or role of Lcn2 in CNS inflammation. Therefore, here we investigated the
regulation and possible function of Lcn2 in the CNS following peripheral lipopolysaccharide (LPS) injection in mice.
Methods: A murine model for systemic endotoxemia was used in this study. Wild type or Lcn2 KO mice (both
genotypes C57BL/6 strain) were given either a single or dual, staggered intraperitoneal injections of purified E. coli
LPS or vehicle alone. The brain was examined for the expression and location of Lcn2 mRNA and protein and
various markers for neuroinflammation were analyzed.
Results: Although undetectable under physiological conditions, both Lcn2 mRNA and protein were induced to
high levels in the brain after LPS injection. By contrast, RNA corresponding to the putative Lcn2 (termed 24p3R)
receptor was present at high levels in the normal brain and remained unaltered by LPS injection. Differences
between Lcn2 and 24p3R mRNA expression were found at the anatomic and cellular level. Endothelial cells,
microglia and the choroid plexus but not neurons were identified as the main cellular sources for Lcn2 mRNA in
the CNS. By contrast, 24p3R mRNA was detected in neurons and the choroid plexus only. Lcn2 protein was found
to have a similar cellular localization as the corresponding RNA transcripts with the exception that subsets of
neurons were also strongly positive. Various inflammatory, glial, and iron handling markers were analyzed and
found to have similar alterations between WT and Lcn2 KO animals.
Conclusions: 1) Lcn2 production is strongly induced in the CNS by systemic LPS injection, 2) in addition to Lcn2
production at key gateways of bacterial entry to the CNS, neurons may be a target for the actions of Lcn2, which
is apparently taken up by these cells, and 3) the cellular functions of Lcn2 in the CNS remain enigmatic.
Background
Lipocalin 2 (Lcn2; also known in humans as neutrophil
gelatinase-associated lipocalin (NGAL) [1] and in the
mouse as 24p3 [2]) is a small, secreted protein that
belongs to the lipocalin family which comprises over 20
members [3]. Despite the low sequence homology
(around 20%), all lipocalin family members share a com-
mon tertiary structure, namely an eight-stranded, con-
tinuously hydrogen bonded anti-parallel ß-barrel [3].
Whereas most lipocalins bind to lipophilic molecules,
Lcn2 binds to a class of bacterial metal-binding mole-
cules called siderophores [4].
Lcn2 is involved in anti-microbial defence by seques-
tering iron [5]. Iron is essential for bacterial growth and
bacteria such as Escherichia coli obtain iron from the
host by producing siderophores that bind iron and
transport it back into the bacterial cell. Studies in vitro
have demonstrated that Lcn2 has a bacteriostatic effect
via the binding of siderophore molecules, thereby
restricting the availability of iron to bacteria [5]. Lcn2
mRNA is upregulated markedly following LPS-mediated
activation of the toll-like receptor (TLR) 4 signalling
pathway [6]. Further supporting a role of Lcn2 as a bac-
teriostatic agent, mice lacking Lcn2 are markedly more
susceptible to bacterial infection compared with wild
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Lcn2 is a key participant in the host response where it
has the important function to inhibit the growth of bac-
teria by starving these organisms of essential iron.
While Lcn2 is well accepted to be a secreted protein
that binds iron-loaded microbial siderophores, further
functions remain unclear. High expression of Lcn2 has
been documented in certain organs including the uterus,
kidney and mammary glands [8,9]. As such a wide range
of cellular functions have been attributed to Lcn2,
including a role as an acute phase protein [10], an indu-
cer of tissue involution in reproductive tissues [11], con-
trol of kidney tubular cell development [12] and
stimulation of apoptosis in hematopoietic cells [8,9].
Recently, Lcn2 was described as a pro-apoptotic factor
for murine microglial cells [13] and an autocrine media-
tor of reactive astrocytosis [14]. Mice with a targeted
disruption of the gene for Lcn2 do not show any spon-
taneous developmental changes nor apoptotic defects
[6,7]. Therefore, if Lcn2 has any role in these proposed
cellular processes this is clearly redundant. Nevertheless,
the discovery of a putative cell surface receptor (termed
24p3R) for Lcn2 on mammalian cells [8], makes it likely
that Lcn2 may also modulate cellular function. In sup-
port of this, the 24p3R was found to mediate the inter-
nalisation of Lcn2 by endocytosis, leading to apoptosis
[8]. The 24p3R is widely expressed in different organs
[8] but expression in the CNS has so far been little
investigated. Overall, the discovery of 24p3R suggests
that, in addition to its extracellular anti-microbial func-
tion, Lcn2 might have certain intracellular functions,
which remain to be defined.
To date the regulation and role of Lcn2 and its recep-
tor in the CNS remains relatively unclear. In this study,
the expression and localization of Lcn2 RNA and pro-
tein, as well as 24p3R RNA in the CNS were investi-
gated in a previously described model for systemic LPS-
induced endotoxemia [15]. In addition, in view of its
reported functions as an acute-phase reactant [10] and a
modulator glial cell function [13,14] the contribution of
Lcn2 to the host response was examined in the CNS fol-
lowing systemic LPS administration.
Methods
Animals
Wild type mice (WT; C57BL/6 background) were pur-
chased from the Animal Resources Centre, Canning
Vale, WA, AUS. Lcn2 KO mice (C57BL/6 background;
[6]) were obtained originally from Dr. Alan Aderem,
Institute for Systems Biology, Seattle, USA and a breed-
ing colony was established at the University of Sydney.
To match strain background as much as possible, Lcn2
sufficient mice used as controls were derived from the
interbreeding of WT mice with Lcn2 KO mice. Lcn2
heterozygotes were then further interbred to derive
Lcn2 KO or WT animals which were used in this study.
Ethical approval for the use of all mice in this study was
obtained from the University of Sydney Animal Care
and Ethics Committee.
Lipopolysaccharide (LPS)-induced endotoxemia model
A previously described model for systemic bacterial
infection-induced CNS inflammation was employed in
which mice were given either single or dual, staggered
injections of LPS [15]. The second dose of LPS mimics
a more sustained gram-negative bacteremia in which we
have shown previously, provokes a considerably
enhanced inflammatory reaction in the brain [15]. In the
current study, three-month old mice were injected intra-
peritoneally (i.p.) with a sub-lethal dose (2 μg/mg body
weight) of LPS (from E. coli serotype 026:B6; Sigma-
Aldrich, Castle Hill, NSW, AUS) in sterile 0.15 M NaCl.
Control mice received an i.p. injection of 0.15 M NaCl
alone. Mice received either a single injection and were
euthanized after 4 h or 24 h, or dual injections given 16
h apart and were euthanized 4 h or 24 h after the sec-
ond injection.
Cell culture and treatment
The C8-B4 microglial cell line [16] was obtained from
the American Type Culture Collection (Manassas, VA,
USA). Cells were cultured in growth medium consisting
of Dulbecco’s modified Eagle’s medium (DMEM; Invi-
trogen, Mt. Waverley, VIC, AUS) supplemented with
10% FBS (Thermo Scientific, Noble Park, VIC, AUS)
and penicillin and streptomycin (Invitrogen). At 75%
confluency cells were washed and the medium replaced
with fresh DMEM medium containing LPS (E. coli sero-
type 026:B6), polyinosinic:polycytidylic acid (poly I:C) or
pertussis toxin (PTX) (all from Sigma-Aldrich) and the
cultures incubated for a further 4 h at 37°C before
extraction of RNA (see below).
Isolation of RNA
The brain and liver were removed immediately from
euthanized mice, snap frozen in liquid nitrogen and
stored at -80°C pending RNA extraction. Total RNA
was extracted with TriReagent (Sigma-Aldrich) accord-
ing to the Manufacturer’s protocol. For cells, after
removal of treatment medium, cultures were washed
once in PBS and RNA prepared using TriReagent per-
formed according to the Manufacturer’s protocol.
RNA Probes
The specific target sequences used to generate probes
for murine Lcn2 and the 24p3R for RNase protection
assay (RPA) and in situ hybridization (ISH) are listed in
Table 1. The generation and sub-cloning of the specific
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PCR-assisted directional cloning according to our pre-
viously published methods [17]. Briefly, cDNA was
obtained from 10 μg total RNA (isolated from the brain
of mice at 4 h after i.p. injection of LPS as described
above) by reverse transcriptase-polymerase chain reac-
tion (RT-PCR) using oligo (dT) primers12-18 and 1 μlo f
Superscript II RT (0.5 μg/μl) as recommended by the
manufacturer. The synthesized cDNA was then used as
a template and subjected to amplification by PCR. In
the PCR, a mixture of 8 μl 10X PCR buffer (without
MgCl2), 8 μl5 0m MM g C l 2,0 . 5μl Taq polymerase (5
U/μl), 20 μl RT reaction product from above, together
with 5 μl2n M5 ’ primer and 5 μl2n M3 ’ primer in a
total volume of 100 μl was prepared. Each cDNA pro-
duct was then directionally cloned into pGEM-4Z (Pro-
mega, Madison, WI, USA) plasmid that incorporate T7
and SP6 RNA polymerase promoters flanking the clon-
ing region defined by the EcoRI or HindIII restriction
enzyme sites. The presence of the correct insert
sequence was confirmed by sequencing analysis pro-
vided by SUPAMAC (Sydney University Prince Alfred
Macromolecular Analysis Centre, Sydney, AUS). Diges-
tion of the transformed plasmids with either EcoRI or
HindIII, transcription with T7 or SP6 RNA polymerase
(both from Promega) yielded anti-sense (T7) or sense
(SP6) RNA probes respectively. The generation of the
additional chemokine, cytokine and host response RPA
probe sets used in this study was described previously
[18-20]. The genomic clone RPL32-4A served as a
probe for the ribosomal protein L32 as described pre-
viously [21]. This was included as an internal control for
RNA loading during RPA analysis.
RNase protection assay
RPAs were performed as described previously [20] using
the probe sets described above consisting of an equimo-
lar pool of EcoRI-linearized templates (15 ng each).
RNA levels were quantified from scanned autoradio-
grams by densitometry using NIH Image software (ver-
sion 1.63) as described previously [17].
Dual in situ hybridization and immunohistochemistry
Brains from LPS- or vehicle-injected mice were removed
and fixed overnight in ice-cold 4% paraformaldehyde in
phosphate-buffered saline (pH 7.4). Paraffin-embedded
sections (10 μm) were incubated with [
33P]-labeled cRNA
probes transcribed from either the EcoR1 (antisense) or
HindIII (sense) linearized Lcn2 or 24p3R plasmids and
processed for in situ hybridization as described pre-
viously [20]. Sections were then processed for immuno-
histochemistry to detect microglia and endothelial cells
(biotinylated lectin from Lycopersicon esculentum; Sigma-
Aldrich), neurons (mouse anti-neuron specific nuclear
antigen (NeuN) antibody; Chemicon, Boronia, Vic, AUS),
and astrocytes (rabbit anti-cow glial fibrillary acidic pro-
tein antibody; DAKO Cytomation; Botany, NSW, AUS).
All antibodies were used at a final concentration of 5 μg/
ml. Bound antibody was detected using Vectastain ABC
kits (Vector Laboratories, Burlingame, CA, USA), and
diaminobenzidine/peroxide reagent (Vector) was used as
the peroxidase substrate.
Immunohistochemistry (IHC)
To study the cellular distribution of Lcn2, the astrocyte
marker, GFAP or the microglial marker, IBA-1, IHC was
performed on paraffin-embedded sections of brain. After
deparaffinization in xylene and rehydration in a graded
ethanol series, epitope retrieval was performed. For Lcn2
IHC, tissue sections were digested with proteinase K (24
μg/ml; Promega) in 5 × TE (15 min at 37°C) and then
washed twice with PBS. For GFAP and IBA-1 IHC, tissue
sections were treated as described [22]. Following epitope
retrieval, sections for Lcn2 IHC were blocked in PBS plus
10% BSA while sections for GFAP or IBA-1 IHC were
blocked in TBS plus 5% goat serum. Sections were then
incubated with goat anti-Lcn2 antibody (1:20; R&D Sys-
tems, Minneapolis, MN USA), mouse anti-GFAP anti-
body (1:1000; Sigma-Aldrich), or rabbit anti-IBA-1
antibody (1:100; WAKO, Osaka, Japan) for 1 h at room
temperature. After washing (x3) in PBS sections were
incubated with biotin-coupled anti-goat, anti-mouse or
anti-rabbit secondary antibody (all from Vector) for 40
min at room temperature. Following washing, streptavi-
din-coupled HRP was applied to the slides for 30 min.
Subsequently, specific signals were visualized with
NovaRED colour reagent (Vector), counterstained with
hematoxylin and the slides examined by bright-field
microscopy. To evaluate the specificity of the staining for
Lcn2, some sections were incubated either with primary
antibody that had been pre-incubated with recombinant
Lcn2 in a 20-fold excess or with non-immune goat
serum. In addition, immunostaining with the anti-Lcn2
antibody was performed on sections prepared from the
brain of LPS-treated Lcn2 KO mice.
Western Blot Analysis
To investigate the level of Lcn2, transferrin receptor-1
(TFR-1), GFAP or IBA-1 protein, Western blot was
Table 1 cDNA target sequences used to generate Lcn2
and 24p3R probes
Gene Target Sequence (bp) Length (bp) GenBank No.
Lcn2 301-606 305 X14607
24p3R 1449-1554 106 NM_021551
24p3R-ISH 1275-1554 280 NM_021551
RPL32-4A 61 - 139 78 K02060
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was removed and bisected down the sagittal midline and
the complete brain half snap frozen in liquid nitrogen.
Protein lysates were prepared by homogenizing snap
frozen hemibrain in lysis buffer containing 1.5% Nonidet
P-40, 10% glycerol, 1 mM DTT (all from Sigma-
Aldrich), protease and phosphatase inhibitors (Calbio-
chem; Kilsyth, Vic, AUS). Protein concentration of the
samples was estimated by Bradford Assay (Bio-Rad
Laboratories, Gladesville, NSW, AUS) or BCA Protein
Assay (Thermo Scientific). An aliquot of sample corre-
sponding to 50 μg/30 μg of protein was separated on a
precast NuPAGE gradient gel (4 - 12%; Invitrogen) by
electrophoresis at 150 V/40 mA per gel. Following elec-
trotransfer to a PVDF membrane, membranes were
blocked with 10% milk/5% milk in 20 mM Tris base, 15
mM NaCl, 0.1% Tween 20 (pH 7.4) (TBS-T). Mem-
branes were then incubated with the primary antibodies:
goat anti-Lcn2 (1:1500; R&D Systems), mouse anti-
transferrin receptor (TFR-1; 1:5000; Invitrogen), rabbit
anti-GFAP (1:5000; Abbiotec, San Diego, CA USA), rab-
bit anti-IBA-1 (1:2000; WAKO), or mouse anti-GAPDH
(1:50000; Merck Millipore, Temecula, CA USA) over-
night at 4°C, followed by washing in TBS-T, 1 h block-
ing in 5% milk in TBS-T and a 1 h incubation with
peroxidase-coupled secondary antibody anti goat, anti
mouse (1:40000; Sigma-Aldrich) or anti rabbit (1:40000;
Santa Cruz Biotechnology Inc., Santa Cruz, CA USA) at
room temperature. Bound antibody signal was detected
using ECL reagent (GE Healthcare, Castle Hill, NSW,
AUS). For quantification of Western blots, densitometric
analysis of each band was performed using NIH Image
1.63 software. The density of the individual protein
bands were normalized to that of the loading control
(GAPDH) and the mean ± S.E.M calculated using Prism
4 software (GraphPad Inc. San Diego, CA USA).
Statistical analysis
For RPA and Western blot data the statistical signifi-
cance of any differences was determined either by one-
way ANOVA or unpaired, two-tailed t-test as indicated
in the figure legend calculated using Prism 4 software
(GraphPad). Following ANOVA analysis Tukey’so r
Dunnette’s multiple comparision tests were performed
as indicated in the Figure legend. A difference was con-
sidered as statistically significant with a p < 0.05.
Results
LPS-induced expression of Lcn2 and constitutive
expression of the 24p3R genes in the brain
To examine the expression of the genes for Lcn2 and
24p3R and determine whether these were regulated in
the CNS, a model of bacterial sepsis was employed in
which mice received single or staggered, dual i.p. injec-
tions of LPS [15]. No Lcn2 mRNA was detectable in the
brain (Figure 1A) whereas a low level of Lcn2 mRNA
Figure 1 Lcn2 and 24p3R mRNA levels in the brain and liver following intraperitoneal injection of LPS. Mice were injected i.p. with
sterile 0.15 M NaCl with or without LPS (50 μg) and euthanized after 4 h or 24 h. An extra group of mice received a second LPS injection (dual)
16 h later, and were euthanized 4 h after the second injection. Total RNA was extracted from the brain (A) and the liver (B) and 5 μg analyzed
by RPA as described in the Materials and Methods. Quantification of the Lcn2 and 24p3R RNA levels by densitometry (C). For statistical analysis
an unpaired, two-tailed t-test was used. For statistical significance * p < 0.05 for LPS- versus vehicle-treated control mice (p < 0.05).
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l i v e rw a si n c l u d e di nt h i se x p e r i m e n ta sac o n t r o lo r g a n
since strong up-regulation of Lcn2 in the liver following
LPS-stimulation has been described previously [6]. After
LPS challenge, the level of Lcn2 mRNA increased signifi-
c a n t l yi nb o t ho r g a n s( F i g u r e1 A & 1 B )w i t ham o r ep r o -
nounced increase in the liver (Figure 1B&1C) compared
with the brain (Figure 1A&1C). In the liver, the Lcn2
mRNA level was increased 25- and 21-fold at 4 h and 24 h
after a single LPS injection, respectively and 46-fold after
dual LPS injections (Figure 1C). In the brain, the Lcn2
mRNA level in LPS-treated mice was increased 10- and 5-
fold after the 4 h and 24 h single LPS injections, respec-
tively and 21-fold after dual LPS injections (Figure 1C).
In the liver of control or LPS-treated mice 24p3R
mRNA was not detectable (Figure 1B). By contrast,
strong constitutive expression of 24p3R mRNA was pre-
sent in the brain of control mice, the level of which was
not altered by LPS injection (Figure 1A&1C).
In summary, in normal mice, Lcn2 mRNA was
induced to high levels in the liver and brain, following
systemic LPS challenge. By contrast, the gene for 24p3R
was expressed constitutively in the brain but not in the
liver and the mRNA levels for this Lcn2 receptor gene
were not altered by LPS challenge.
LPS-regulated production of Lcn2 protein in the brain
We next determined if the Lcn2 protein levels in the
brain paralleled the changes observed at the RNA level
(Figure 2A&2B). By immunoblot analysis, no bands were
detectable in lysates of brain from untreated mice. How-
ever, at 4 h following LPS injection a weak band was
detectable that corresponded with the known size (24
kDa) of Lcn2. The intensity of this band was increased
significantly by 24 h after a single LPS injection and was
similarly increased to high levels after dual LPS-injec-
tions. The specificity of the immunoblot analysis for
Lcn2 was confirmed using brain lysates from Lcn2 KO
mice (Figure 2C). No bands were detectable in lysates of
brain from PBS-treated WT or Lcn2 KO mice. However,
following dual injections of LPS a strong band corre-
sponding to Lcn2 was clearly present in lysates of brain
from WT but not Lcn2 KO mice (Figure 2C).
These results validated the specificity of the Lcn2 anti-
body used in our studies and showed that similar to
Lcn2 mRNA, Lcn2 protein was markedly induced in a
time-dependent fashion in the brain following systemic
LPS challenge.
Differential anatomic localization of Lcn2 and 24p3R RNA
in the CNS during LPS-induced endotoxemia
To identify the anatomical localization of the Lcn2 and
24p3R RNA transcripts in the brain, in situ hybridization
was performed on brain sections from LPS-injected mice
using anti-sense and sense RNA probes complementary
to the Lcn2 and 24p3R mRNA transcripts (Figure 3).
In parallel with the findings for the RPA, strong
24p3R RNA hybridization signal was detectable at
Figure 2 Lcn2 protein levels in the brain following intraperitoneal injection of LPS. Mice were treated as shown. Total protein was
extracted from the brain and 50 μg analyzed by Western blot (A) as described in the Materials and Methods with quantification (B) of the Lcn2
protein relative to GAPDH loading control. Comparison of Lcn2 protein level by Western blot (C) in brain from WT versus Lcn2 KO mice after
dual LPS-treated mice. For statistical significance *, p < 0.05 for LPS-treated mice versus control mice (p ≤ 0.05).
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mice (Figure 3A). The pattern of hybridization signal
was distributed widely throughout major gray matter
regions of the brain including the cortex and thalamus
as well as in various neuronal populations such the
granule layer of the cerebellum. However, the highest
levels of 24p3R RNA hybridization signal were observed
in the dentate gyrus (Figure 3A; arrow) and pyramidal
cell layers of the hippocampus and in the choroid plexus
(Figure 3A; arrowhead). A comparison of the hybridiza-
tion of the 24p3R antisense (Figure 3B) versus sense
(Figure 3C) RNA probes confirmed that pattern of
hybridization seen for the antisense probe was specific.
Comparable with the RPA findings above, little, if any,
detectable hybridization signal was seen for Lcn2 RNA
in brain from PBS-injected control mice (Figure 3D). By
contrast, in brain from 4 h LPS-injected mice, a punc-
tate pattern of Lcn2 RNA hybridization signal was
Figure 3 Anatomical localization of Lcn2 and 24p3R RNA in the brain following intraperitoneal injection of LPS.B r a i nw a sr e m o v e d
from mice at different times following LPS injection, fixed in ice-cold 4% PBS-buffered paraformaldehyde and paraffin-embedded sagittal
sections (10 μm) subjected to ISH as described in the Materials and Methods. Hybridization was performed with either 24p3R (A&B) and Lcn2
(D&E) anti-sense or 24pR3 (C) and Lcn2 (F) sense cRNA probes.
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enchyma. At 24 h, the overall pattern of hybridization
signal remained similar but was decreased as compared
with the 4 h LPS-injected mice. In brain from dual LPS-
injected mice, Lcn2 RNA hybridization signal was high-
est and in addition to expression throughout the par-
enchyma also included strong expression in the choroid
plexus (Figure 3D; arrow) and meninges (Figure 3D;
arrowhead). In contrast with dual LPS-treated wild type
mice (Figure 3E), no hybridization signal above the
sense control levels (not shown) was detectable in brain
from Lcn2 KO mice (Figure 3F) following dual injec-
tions of LPS.
In summary, these findings confirmed the strong
induction of Lcn2 RNA in the brain following LPS treat-
ment and showed that the Lcn2 RNA was localized to
cell populations scattered uniformly throughout the
brain parenchyma as well as the choroid plexus. By con-
trast, 24p3R RNA was present at high levels throughout
the brain from control and LPS-treated mice and
appeared to be localized to mainly various neuronal
populations as well as the choroid plexus.
Distinct cellular localization of Lcn2 and 24p3R RNA in
the CNS during LPS-induced endotoxemia
To determine the cellular sources of the Lcn2 and
24p3R RNA transcripts, ISH was combined with immu-
nohistochemistry that allowed for the identification of
neurons (NeuN), astrocytes (GFAP), microglia (lectin)
and endothelium (lectin). No specific signal for Lcn2
RNA was detected above the sense controls in brain
from vehicle-injected mice (Figure 4A). In contrast, in
brain from mice following dual LPS injections, Lcn2
RNA hybridization signal localized to the vascular
endothelium (Figure 4B&4D; arrowheads) as well as
some surrounding non-neuronal cells, that, based on
nuclear morphology were presumed to be microglia
(Figure 4B; white arrows) which was confirmed by lectin
stain (Figure 4D; white arrows). The meninges also
exhibited Lcn2 RNA hybridization (not shown). The
highest level of Lcn2 RNA hybridization signal was
observed in the choroid plexus (Figure 4C; asterisk).
However, no signal was detectable in neurons (Figure
4B; arrows) or astrocytes (not shown). High Lcn2 RNA
hybridization signal was found in cells in close proximity
to neurons presumably microglial cells (white arrows) as
well as vascular endothelium (black arrows).
In contrast to Lcn2 RNA, 24p3R RNA was localized
almost exclusively to neurons in the brain, with a high
level in cortical neurons (Figure 4E; black arrows), hip-
pocampal dentate gyrus and granule neurons (data not
shown) and Purkinje neurons of the cerebellum (data
not shown). Furthermore, a high level of 24p3R RNA
was also observed in the choroid plexus (Figure 4F;
black arrows). No 24p3R RNA was detectable in astro-
cytes, microglia or blood vessels (Figure 4E&4F; white
arrows). There was no detectable difference in either the
level or cellular distribution of the 24p3R RNA expres-
sion in brain from vehicle-treated and LPS-treated mice.
In summary, these findings indicated that the cellular
localization of Lcn2 RNA and its receptor 24p3R RNA
in the brain was on the whole distinct, with the excep-
tion of the choroid plexus.
Localization of Lcn2 protein in the brain of mice with
LPS-induced endotoxemia
We next examined the distribution of Lcn2 protein in
the CNS by immunohistochemistry. The specificity of
the antibody used in these studies was confirmed by the
absence of staining (data not shown) in the sections
incubated with either non-immune goat serum or after
adsorption of the antibody with specific Lcn2 immuniz-
ing peptide. In addition, a similar lack of staining was
observed in brain sections from Lcn2 KO mice that had
been given dual injections of LPS (not shown).
Consistent with the results for the Lcn2 RNA, and
similar to the results obtained in LPS-treated Lcn2 KO
mice, Lcn2 protein was not detectable in the CNS of
control mice (Figure 5A). However, at 4 h after LPS-
injection, Lcn2 protein was clearly detectable almost
exclusively in endothelial cells in numerous blood ves-
sels throughout the brain (Figure 5B; arrows). In addi-
tion to cytoplasmic staining, abundant nuclear staining
of the endothelial cells was also evident (Figure 5B;
arrowheads). At 24 h after LPS injection, Lcn2 protein
accumulated further in vessels throughout the CNS as
well as in ramified parenchymal cells identified as
microglia (Figure 5C; arrows). In addition, at this time-
point there was also strong staining of cells with the
morphology and location of epithelial cells in the chor-
o i dp l e x u s( F i g u r e5 D ;a r r o w s ) .U n e x p e c t e d l y ,p o s i t i v e
staining for Lcn2 protein was observed in specific neu-
ronal populations in the cortex (Figure 5E; arrows), hip-
pocampus (not shown), ventral forebrain (not shown)
and Purkinje neurons of the cerebellum (Figure 5F;
arrows). Finally, diffuse staining of the parenchyma was
evident in various regions of the brain (Figure 5C&5E;
asterisk). A similar pattern of staining for Lcn2 protein
was observed in the brain from mice following dual LPS
injections when compared with 24 h after LPS injection.
Together with the findings from ISH, these results
indicated that the predominant Lcn2 producer cells in
the CNS of mice with LPS-induced endotoxemia are
endothelial cells, choroid plexus-associated cells and
microglia. Interestingly, however, there was a marked
dichotomy between the ISH and IHC results with regard
to various neurons in which Lcn2 RNA was not detect-
able but Lcn2 protein was clearly present.
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Page 7 of 15Figure 4 Cellular localization of Lcn2 and 24p3R RNA in the brain following intraperitoneal injection of LPS. Paraffin-embedded sagittal
sections (10 μm) were subjected to ISH followed by immunohistochemistry as described in the Materials and Methods. A. Brain section from
vehicle-injected control mouse hybridized with Lcn2 anti-sense cRNA probe and immunostained for NeuN. B-D. Brain sections from dual LPS-
treated mice hybridized with Lcn2 anti-sense cRNA probe and immunostained for NeuN (B) and lectin (C&D). E-F. Brain sections from vehicle-
injected control mice hybridised with 24p3R anti-sense cRNA probe and immunostained for NeuN (E) or lectin (F).
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Page 8 of 15Figure 5 Cellular localization of Lcn2 protein in the brain following intraperitoneal injection of LPS. Paraffin embedded sections (5 μm)
were stained by immunohistochemistry to detect Lcn2 protein as described in the Materials and Methods. A. Brain section from a PBS-injected
control mouse. B-F. Brain sections from mice at 24 h following a single intraperitoneal injection of LPS.
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Page 9 of 15Microglial cells respond to LPS and poly I:C with
induction of Lcn2 but lack detectable expression of
24p3R
The findings above indicated that LPS-mediated induc-
tion of Lcn2 gene expression by microglia in the brain
following systemic injection of LPS. We next examined
whether various pathogen associated molecules includ-
ing LPS, dsRNA (poly I:C) and PTX could directly mod-
ulate Lcn2 or 24p3R mRNA levels in cultured C8
microglial cells (Figure 6). A significant dose-dependent
increase in Lcn2 mRNA levels was mediated by both
LPS and poly I:C. A small increase in Lcn2 mRNA
occurred in response to treatment with PTX, however,
this was not significant when compared with the vehi-
cle-treated control cells. In contrast to Lcn2, 24p3R was
not detectable in C8-microglia cells with or without
treatment. These findings showed that in C8 microglial
cells, LPS as well as double-stranded RNA is capable of
inducing the expression of the Lcn2 gene but these cells
appear to lack 24p3R.
Various markers of the host response to LPS showed
similar changes in WT and Lcn2 KO mice
L c n 2m a yb ea na c u t e - p h a se reactant [10] and may
modulate cellular iron metabolism [8]. In addition, Lcn2
has been suggested to mediate microglial [13] and
astroglial [14] activation in response to cytotoxins. Here
we employed Lcn2 KO mice to determine if Lcn2 played
ar o l ei nt h ec e r e b r a lh o s tresponse to LPS-induced
endotoxemia.
In brain from WT mice, dual injections of LPS
induced a significant increase in the levels of a number
of host response (GFAP, EB22/5, CD11b, ICAM-1 and
A20), chemokine (CXCL2, CXCL10, CCL2, CCL4,
CCL5 and CCL7) and proinflammatory cytokine (IFN-g,
TNF-a, IL-6, IL-1a and IL-1b) mRNA transcripts at 4 h
following the second injection of LPS (Figure 7). An
almost identical change in the levels of all these mRNA
transcripts was observed in similarly treated Lcn2 KO
mice. At 24 h following the second LPS injection, with
the exception of the Mac1, EB22 and GFAP mRNAs
which remained elevated, there was a general decrease
in the remaining mRNA transcripts all of which were
similarly changed between WT and Lcn2 KO samples
(data not shown). These findings suggested that the
absence of Lcn2 was not associated with any detectable
change in the cerebral host response to systemic LPS
injection.
We next examined whether markers for iron handling,
the transferrin receptor (TFR-1) and astrocyte (GFAP)
and microglial (IBA-1) activation were altered by LPS-
induced endotoxemia. In brain from WT and Lcn2 KO
mice the level of TFR-1 was similar and remained unal-
tered at 4 h and 24 h after dual LPS injections. In con-
trast to GFAP mRNA, which was significantly increased
after dual LPS injection (see Figure 7), GFAP protein
was not significantly altered from control levels at either
4 h or 24 h (not shown) after dual LPS injections in
either WT or Lcn2 KO mice (Figure 8A &8B). Similar
to GFAP, the level of the microglial marker IBA-1 did
not differ significantly between WT and Lcn2 KO mice
and remained unaltered following LPS injection in either
WT or Lcn2 KO mice (Figure 8A &8B). To determine
further whether Lcn2 may contribute to glial activation
in response to LPS-induced endotoxemia we performed
immunohistochemical analysis of brain sections. Immu-
nostaining for GFAP (Figure 8C) revealed similar mor-
phological appearance and GFAP levels in astrocytes
from WT and Lcn2 KO mice. Little observable change
was found for these parameters in either WT or Lcn2
KO mice at 4 h or 24 h (not shown) after LPS injection.
Both IBA-1 staining and microglial morphology was
similar for WT and Lcn2 KO mice in which the cells
exhibited a highly ramified appearance with fine pro-
cesses that extended throughout the parenchyma of the
brain (Figure 8C). However, following dual LPS injec-
tions the microglia underwent a marked morphological
change in which the processes appeared retracted and
were more stunted and the cells more swollen in
appearance in both WT and Lcn2 KO mice (Figure 8C).
Figure 6 Regulation of Lcn2 mRNA levels in C8 microglial cells.
The C8 microglial cell line was grown to 75% confluency and
treated for 4 h at 37°C as indicted. Total RNA was isolated and
analyzed by RPA as described in the Materials and Methods. For
statistical analysis one-way ANOVA with Dunnett’s multiple
comparison test was used. For statistical significance * p < 0.05
versus untreated control (Con).
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Page 10 of 15Figure 7 The level of various host response, chemokine and cytokine mRNA transcripts in the brain of WT versus Lcn2 KO mice
following intraperitoneal injection of LPS. Mice were injected i.p. with sterile PBS with or without LPS and received a second LPS injection
(dual) 16 h later and euthanized 4 h after the second injection. Total RNA was extracted from the brain and 10 μg analyzed by RPA as described
in the Materials and Methods. For quantification of the mRNA levels, densitometry was performed on film autoradiographs and corrected for
loading by reference to the L32 loading control. For statistical analysis, one-way ANOVA with Tukey’s multiple comparison test was used. For
statistical significance *, p < 0.05 for LPS-treated mice versus vehicle-injected control mice (p ≤ 0.05).
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Page 11 of 15In total, these data failed to find any significant differ-
ence in the astroglial nor microglial response to LPS
between WT and Lcn2 KO mice.
Discussion
Lcn2 has emerged as a key factor in the host response to
bacterial infection [3]. Moreover, based on recent reports
of cellular receptors that mediate the binding and uptake
of Lcn2 it is likely that Lcn2 may also influence the func-
tion of eukaryotic cells [8,23,24]. Currently little is
known concerning the CNS pathobiology of Lcn2 or its
putative cellular receptor 24p3R [8]. Therefore, here we
investigated the expression and localization of Lcn2 RNA
and protein, as well as 24p3R RNA, in the brain in a
model for systemic LPS-induced endotoxemia. Similar to
the liver, we found that Lcn2 mRNA and protein,
although not detectable in the brain of normal control
mice, were induced by 4 h after a systemic LPS challenge
and increased markedly following a repeated challenge
with the inflammogen. The dynamics of Lcn2 induction
in the brain following LPS administration suggests that in
this tissue as with the liver [6,10], Lcn2 functions as an
Figure 8 Comparison of the astrocyte and microglial response in the brain of WT versus Lcn2 KO mice following intraperitoneal
injection of LPS. Mice were injected i.p. with sterile PBS with or without LPS and received a second LPS injection (dual) 16 h later, and were
euthanized 4 h after the second injection. Total protein was extracted from the brain and 30 μg analyzed by Western blot (A) and quantified (B)
as described in the Materials and Methods. For immunohistochemistry (C) mice were perfused intracardially with ice-cold 4% PBS-buffered
paraformaldehyde the brains removed and immunohistochemistry performed for GFAP or IBA-1 as described in the Materials and Methods.
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Page 12 of 15acute-phase response protein. Consistent with its role as
an acute phase reactant, Lcn2 is secreted from various
cells including microglia [13] and accumulates to high
levels in the blood following intraperitoneal injection of
LPS in mice [6]. In addition, Lcn2 was shown to increase
in the cerebrospinal fluid of LPS-treated mice [25].
Despite a significant reduction in Lcn2 mRNA levels, the
increased accumulation of Lcn2 protein we observed in
the brain at 24 h after LPS treatment suggested that Lcn2
protein is also relatively stable and may undergo limited
turnover in the brain. In contrast to the ligand, we
demonstrated that there is high constitutive expression
of 24p3R in the brain of mice, which was not affected by
systemic LPS administration. In line with our finding
here of CNS and predominant neuronal localization,
DNA sequence analysis revealed that 24p3R corresponds
to the brain type organic cation transporter [8]. Although
it has been reported previously that the 24p3R protein is
present in the liver [8], we failed to detect the corre-
sponding 24p3R mRNA. Therefore, our finding suggests
that unlike the brain, the 24p3R gene is not expressed in
the liver.
A previous study [25] reported that Lcn2 protein
accumulates in the choroid plexus of mice following sys-
temic LPS injection. Our findings here confirm and
extend these observations and illustrated further the
induction of high levels of Lcn2 mRNA in choroid
plexus epithelium indicating that this brain tissue is a
major CNS site for the production of Lcn2. However,
the induction of significant Lcn2 protein levels in the
choroid plexus occurred relatively late after LPS admin-
istration. The earliest detectable induction of Lcn2
mRNA and protein following LPS injection was in the
cerebrovascular endothelium which increased with time.
This vascular site of production likely leads to the initial
accumulation of Lcn2 at the blood-brain barrier inter-
face. Subsequent passage of LPS across the fenestrated
vascular endothelium of the choroid plexus could
account for Lcn2 production at this site, leading to the
additional accumulation of Lcn2 at the blood-CSF bar-
rier. We observed more extensive induction of Lcn2
mRNA, which included parenchymal microglia through-
out the brain following dual injections of LPS. Our stu-
dies revealed that LPS is capable of directly inducing the
production of Lcn2 by the C8 microglial cell line in
vitro. The ability of LPS to activate the expression of the
gene for Lcn2 in mice is crucially dependent on TLR4
signaling [6]. The known pattern of TLR4 expression in
the CNS of mice is consistent with a role for TLR4 in
mediating LPS-induced Lcn2 expression in the choroid
plexus, blood vessels and microglia [26,27]. The finding
that poly I:C, an activator of TLR3 and RNA helicase
signaling [28] also induced Lcn2 gene expression in the
C8 microglia indicates that additional innate signaling
pathways associated with viral infection may also regu-
late the expression of the Lcn2 gene.
Our studies revealed a major discrepancy in the cellu-
lar localization of the Lcn2 RNA versus protein in the
brain following LPS injection. While neurons did not
contain detectable levels of Lcn2 RNA, subsets of these
cells in different regions of the brain stained strongly for
Lcn2 protein. The specificity of the anti-Lcn2 antibody
used in our studies was confirmed via a number of
approaches making it unlikely that this neuronal stain-
ing was non-specific or an artifact. It is possible that
Lcn2 RNA was present but at a very low level in neu-
rons that was undetectable by in situ hybridization his-
tochemistry. An alternativea n dp e r h a p sm o r ep l a u s i b l e
explanation for these findings was that neurons can
actively take up and accumulate Lcn2 that was secreted
by microglia. The finding of diffuse immunostaining for
Lcn2 on the neuropil suggested that relatively high
levels of Lcn2 may accumulate in the extracellular
milieu following systemic LPS administration and there-
fore would be available for cellular uptake. We showed
that neurons had high levels of expression of the 24p3R
gene which encodes for a protein that is known to facili-
tate the binding and cellular uptake of Lcn2 [8]. How-
ever, the distribution of the 24p3R RNA was quite
widespread and included the majority of neurons in the
brain whereas Lcn2 immunostaining was restricted to
specific sub-populations of neurons in different brain
regions. The basis for the restricted localization of Lcn2
t os p e c i f i cn e u r o n si su n k n o w nb u tr a i s e sq u e s t i o n s
about the overall role for 24p3R in this proposed pro-
cess. Recently, megalin (also known as lipoprotein
receptor-related protein-2) was identified as another
putative cellular receptor that supports the uptake of
Lcn2 by human cells [23]. However, it is unclear pre-
sently what the cellular distribution of this putative
Lcn2 receptor is in the brain. Irrespective of the expla-
nation, our findings raise the strong possibility that neu-
r o n sm a yb eat a r g e tf o rt h ea c t i o n so fL c n 2i nt h e
brain.
The robust induction of Lcn2 by LPS and other inflam-
matory stimuli and the linkage of this protein to the
acute-phase response led us to examine various para-
meters of the host response to LPS in the brain in mice
deficient for Lcn2. Our findings here extend those of a
previous study [15] in demonstrating the dramatic induc-
tion of various genes associated with the host response to
staggered peripheral injections of LPS. However, the find-
ings also suggested that Lcn2 does not play a major role
in this process since similar changes were observed in the
level of expression of various cytokine and chemokine
genes as well as the GFAP, CD11b and EB22 genes in
both WT and Lcn2 KO mice following LPS treatment.
Previous studies have suggested that Lcn2 may sensitize
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Page 13 of 15microglia to nitric oxide-induced apoptosis and induce
morphological changes consistent with activation [13].
M o r e o v e r ,s u b s e q u e n tw o r kf r o mt h es a m eg r o u p[ 1 4 ]
reported a similar outcome in astrocytes i.e. Lcn2 sensi-
tized these cells to cytotoxin-induced cell death and
mediated astrocytosis. However, the current study indi-
cated that there was no significant change in either
microglial or astrocyte activation in the brain of Lcn2 KO
mice in response to peripheral LPS treatment. Therefore,
our findings suggest that Lcn2 is not an essential modu-
lator of gliosis in response to LPS in vivo.
Conclusions
Based on the findings from this study, we conclude: 1)
Lcn2 production is strongly induced in the CNS by sys-
temic LPS injection, 2) in addition to Lcn2 production
at key gateways of bacterial entry to the CNS, neurons
may be a target for the actions of Lcn2, which is appar-
ently taken up by these cells and 3) the cellular func-
tions of Lcn2 in the CNS response to systemic LPS
challenge remain unclear and will require further study
to elucidate.
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